BioSpace News Archive

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced the appointment of Wei Wei Chen to the company’s Board of Directors.

Apexigen, Inc. today announced the upcoming presentation of Phase 2 clinical data on the use of intratumoral sotigalimab, Apexigen’s monoclonal antibody targeting CD40, in combination with systemic pembrolizumab for patients with treatment-naïve metastatic melanoma.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive efficacy results from the Phase 1b segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”).

Sequence Bio announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio’s proprietary discovery platform to identify novel dermatologic drug targets.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 20 new employees.

McKesson Corporation announced that it has closed the transaction announced in November 2021 to sell its UK businesses to AURELIUS.

Bicycle Therapeutics plc today announced updated preclinical results providing further evidence for Bicycles as a potential novel antiviral modality against SARS-CoV-2.

Wugen, Inc. announced that management will participate in two upcoming virtual investor conferences in April: 21st Annual Needham Virtual Healthcare Conference Format: Panel titled “Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space” Date/Time: Thursday, April 14, 2022 at 11:00 a.m.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open.

Twist Bioscience Corporation and MediSix Therapeutics today announced a collaboration to discover novel antibodies against five undisclosed targets.